AstraZeneca EPS - Earnings per Share 2006-2019 | AZN
AstraZeneca annual and quarterly earnings per share history from 2006 to 2019. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- AstraZeneca EPS for the quarter ending September 30, 2019 was $0.23, a 35.29% increase year-over-year.
- AstraZeneca EPS for the twelve months ending September 30, 2019 was $0.93, a 2.94% decline year-over-year.
- AstraZeneca 2018 annual EPS was $0.85, a 28.27% decline from 2017.
- AstraZeneca 2017 annual EPS was $1.19, a 14.13% decline from 2016.
- AstraZeneca 2016 annual EPS was $1.38, a 23.77% increase from 2015.
| AstraZeneca Annual EPS |
| 2018 |
$0.85 |
| 2017 |
$1.19 |
| 2016 |
$1.38 |
| 2015 |
$1.12 |
| 2014 |
$0.49 |
| 2013 |
$1.02 |
| 2012 |
$2.47 |
| 2011 |
$3.63 |
| 2010 |
$2.79 |
| 2009 |
$2.60 |
| 2008 |
$2.10 |
| 2007 |
$1.87 |
| 2006 |
$1.93 |
| 2005 |
$1.46 |
| AstraZeneca Quarterly EPS |
| Q3 2019 |
$0.23 |
| Q2 2019 |
$0.05 |
| Q1 2019 |
$0.24 |
| Q4 2018 |
$0.41 |
| Q3 2018 |
$0.17 |
| Q2 2018 |
$0.14 |
| Q1 2018 |
$0.14 |
| Q4 2017 |
$0.51 |
| Q3 2017 |
$0.27 |
| Q2 2017 |
$0.19 |
| Q1 2017 |
$0.21 |
| Q4 2016 |
$0.73 |
| Q3 2016 |
$0.40 |
| Q2 2016 |
$0.00 |
| Q1 2016 |
$0.26 |
| Q4 2015 |
$0.32 |
| Q3 2015 |
$0.30 |
| Q2 2015 |
$0.28 |
| Q1 2015 |
$0.22 |
| Q4 2014 |
$-0.13 |
| Q3 2014 |
$0.10 |
| Q2 2014 |
$0.32 |
| Q1 2014 |
$0.20 |
| Q4 2013 |
$-0.21 |
| Q3 2013 |
$0.50 |
| Q2 2013 |
$0.33 |
| Q1 2013 |
$0.41 |
| Q4 2012 |
$0.61 |
| Q3 2012 |
$0.60 |
| Q2 2012 |
$0.63 |
| Q1 2012 |
$0.64 |
| Q4 2011 |
$0.58 |
| Q3 2011 |
$1.27 |
| Q2 2011 |
$0.77 |
| Q1 2011 |
$1.04 |
| Q4 2010 |
$0.57 |
| Q3 2010 |
$0.54 |
| Q2 2010 |
$0.73 |
| Q1 2010 |
$0.96 |
| Q4 2009 |
$0.54 |
| Q3 2009 |
$0.73 |
| Q2 2009 |
$0.59 |
| Q1 2009 |
$0.74 |
| Q4 2008 |
$0.43 |
| Q3 2008 |
$0.60 |
| Q2 2008 |
$0.56 |
| Q1 2008 |
$0.52 |
| Q4 2007 |
$0.43 |
| Q3 2007 |
$0.46 |
| Q2 2007 |
$0.48 |
| Q1 2007 |
$0.51 |
| Q4 2006 |
$0.47 |
| Q3 2006 |
$0.51 |
| Q2 2006 |
$0.51 |
| Q1 2006 |
$0.45 |
| Q4 2005 |
$0.39 |
| Q3 2005 |
$0.38 |
| Q2 2005 |
$0.38 |
| Q1 2005 |
$0.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$126.465B |
$22.090B |
|
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
|
